Antigen Information

General Information of This Antigen (ID: TAR0YLQCG)
Antigen Name
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38)
Gene Name
CD38
Gene ID
952
Synonym
2'-phospho-ADP-ribosyl cyclase;2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase;2'-phospho-cyclic-ADP-ribose transferase;ADP-ribosyl cyclase 1;Cyclic ADP-ribose hydrolase 1;T10;CD38
Sequence
MANCEFSPVSGDKPCCRLSRRAQLCLGVSILVLILVVVLAVVVPRWRQQWSGPGTTKRFP
ETVLARCVKYTEIHPEMRHVDCQSVWDAFKGAFISKHPCNITEEDYQPLMKLGTQTVPCN
KILLWSRIKDLAHQFTQVQRDMFTLEDTLLGYLADDLTWCGEFNTSKINYQSCPDWRKDC
SNNPVSVFWKTVSRRFAEAACDVVHVMLNGSRSKIFDKNSTFGSVEVHNLQPEKVQTLEA
WVIHGGREDSRDLCQDPTIKELESIISKRNIQFSCKNIYRPDKFLQCVKNPEDSSCTSEI

    Click to Show/Hide
Family
Thymidylate 5'-phosphatase family
Function
Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion. Synthesizes the Ca(2+) mobilizer nicotinate-adenine dinucleotide phosphate, NAADP(+), from 2'-phospho-cADPR and nicotinic acid, as well as from NADP(+) and nicotinic acid. At both pH 5.0 and pH 7.4 preferentially transforms 2'-phospho-cADPR into NAADP(+), while preferentially cleaving NADP(+) to cADPR and ADPRP rather than into NADDP(+). Has cADPR hydrolase activity.

    Click to Show/Hide
Uniprot Entry
CD38_HUMAN
HGNC ID
HGNC:1667
KEGG ID
hsa:952
Each Antibody-drug Conjugate and Its Component Related to This Antigen
Full List of The ADC Related to This Antigen
The Numbers of ADCs, Their Three Components, Payload Targets, and Corresponding Diseases for This Antigens
alpha-CD38 mAb
 Antibody Info 
ADC Name Payload Target Linker ADC Info
TE-1146 [1]
Lenalidomide
Undisclosed
Undisclosed
 ADC Info 
Anti-CD38 mAb
 Antibody Info 
ADC Name Payload Target Linker ADC Info
CD38 ADC [2]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
C38A2/C38D8
 Antibody Info 
ADC Name Payload Target Linker ADC Info
CN110997009BADC#40 [3]
CN110997009B ADC#40 Payload
Undisclosed
CN110997009B ADC#40 Linker
 ADC Info 
CN110997009BADC#41 [3]
CN110997009B ADC#41 Payload
Undisclosed
CN110997009B ADC#40 Linker
 ADC Info 
CN110997009BADC#42 [3]
CN110997009B ADC#42 Payload
Microtubule (MT)
CN110997009B ADC#42 Linker
 ADC Info 
CN110997009BADC#43 [3]
CN110997009B ADC#43 Payload
Microtubule (MT)
CN110997009B ADC#42 Linker
 ADC Info 
CN110997009BADC#44 [3]
Duo5
Microtubule (MT)
CN110997009B ADC#40 Linker
 ADC Info 
CN110997009BADC#45 [3]
Duo5
Microtubule (MT)
CN110997009B ADC#45 Linker
 ADC Info 
CN110997009BADC#46 [3]
Duo5
Microtubule (MT)
CN110997009B ADC#46 Linker
 ADC Info 
Daratumumab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
αCD38-MC-I034
Amine-I034
IKZF1/3
MC
 ADC Info 
Dara-DVA-I030
I030
IKZF1/3
MC-DVA-PABC
 ADC Info 
Dara-VA-I034 (4)
I034
IKZF1/3
MC-VA
 ADC Info 
Dara-VA-I034 (8)
I034
IKZF1/3
MC-VA
 ADC Info 
EDC-8 [4]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
AA-A225 [5]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Daratumumab-Compound (Ia) [6]
NeoDegrader P1
Protein cereblon (CRBN)
Daratumumab-Compound (Ia) linker
 ADC Info 
Anti-CD38_VCGP-Dex [7]
Dexamethasone
Glucocorticoid receptor (NR3C1)
Mal-ValCitGlyPro-OH
 ADC Info 
Daratumumab-I-1-1 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-1-1 linker
 ADC Info 
Daratumumab-I-2-1.76 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-2-1.76 linker
 ADC Info 
Daratumumab-I-3-1.39 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-3-1.39 linker
 ADC Info 
Daratumumab-I-4-0.24 [8]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Daratumumab-I-5-0.15 [8]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Daratumumab-I-6-0 [8]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Daratumumab-I-7-0.01 [8]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Daratumumab-I-8-0.04 [8]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Daratumumab-I-9-1.1 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Cetuximab-I-9-0.03 linker
 ADC Info 
Daratumumab-I-9-0.06 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Cetuximab-I-9-0.03 linker
 ADC Info 
Daratumumab-I-10-0.14 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-10-0.08 linker
 ADC Info 
Daratumumab-I-10-0.98 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-10-0.08 linker
 ADC Info 
Daratumumab-I-10-0.08 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-10-0.08 linker
 ADC Info 
Daratumumab-I-11-0.14 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-11-0.05 linker
 ADC Info 
Daratumumab-I-11-0.05 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-11-0.05 linker
 ADC Info 
Daratumumab-I-12-1.44 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-12-1.44 linker
 ADC Info 
Daratumumab-I-13-0.09 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-13-0.09 linker
 ADC Info 
Daratumumab-I-14-0.29 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-14-0.29 linker
 ADC Info 
Daratumumab-I-15-0.74 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-15-0.74 linker
 ADC Info 
Daratumumab-I-16-0.3 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-16-0.3 linker
 ADC Info 
Daratumumab-I-17-0.37 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-17-0.37 linker
 ADC Info 
Daratumumab-I-18-0.15 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Cetuximab-I-18-0.04 linker
 ADC Info 
Daratumumab-I-18-0.05 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Cetuximab-I-18-0.04 linker
 ADC Info 
Daratumumab-I-19-0.2 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-19-0.2 linker
 ADC Info 
Daratumumab-I-20-0.72 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-20-0.72 linker
 ADC Info 
Daratumumab-I-21-0.18 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-21-0.18 linker
 ADC Info 
Daratumumab-I-22--0.18 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-22--0.18 linker
 ADC Info 
Daratumumab-I-23-0.14 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-23-0.14 linker
 ADC Info 
Daratumumab-I-24-0.83 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-24-0.05 linker
 ADC Info 
Daratumumab-I-24-0.05 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-24-0.05 linker
 ADC Info 
Daratumumab-I-25-1.25 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-25-0.1 linker
 ADC Info 
Daratumumab-I-25-0.1 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-25-0.1 linker
 ADC Info 
Daratumumab-I-26--0.1 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-26--0.1 linker
 ADC Info 
Daratumumab-I-27--0.02 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-27--0.02 linker
 ADC Info 
Daratumumab-I-30-0.22 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-30-0.22 linker
 ADC Info 
Daratumumab-I-32-0.28 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-32-0.28 linker
 ADC Info 
Daratumumab-I-33-0.33 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-33-0.33 linker
 ADC Info 
Daratumumab-I-35-2.05 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-35-0.3 linker
 ADC Info 
Daratumumab-I-35-0.3 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-35-0.3 linker
 ADC Info 
Daratumumab-I-36-5.03 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-36-5.03 linker
 ADC Info 
Daratumumab-I-37-5.49 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-37-5.49 linker
 ADC Info 
Daratumumab-I-38-0.52 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Cetuximab-I-38-0.31 linker
 ADC Info 
Daratumumab-I-39-0.36 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Cetuximab-I-39-0.46 linker
 ADC Info 
Daratumumab-I-40-0.4 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Cetuximab-I-40-0.69 linker
 ADC Info 
Daratumumab-I-42-0.13 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-42-0.13 linker
 ADC Info 
Daratumumab-I-43-0.26 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-43-0.26 linker
 ADC Info 
Daratumumab-I-44-0.59 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-44-0.59 linker
 ADC Info 
Daratumumab-I-45-0.64 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Cetuximab-I-45-0.7 linker
 ADC Info 
Daratumumab-I-46-0.43 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-46-0.15 linker
 ADC Info 
Daratumumab-I-46-0.15 [8]
Cetuximab-I-45-0.7 payload
Undisclosed
Daratumumab-I-46-0.15 linker
 ADC Info 
ADC Name Payload Target Linker ADC Info
HuAT12/5-Compound (Ia) [6]
NeoDegrader P1
Protein cereblon (CRBN)
HuAT12/5-Compound (Ia) linker
 ADC Info 
Indatuximab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
Indatuximab-Compound (Ia) [6]
NeoDegrader P1
Protein cereblon (CRBN)
Indatuximab-Compound (Ia) linker
 ADC Info 
JP7623413B2 ExampleADC56 [9]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
JP7560255B2 ControlADC56 [10]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Isatuximab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
Isatuximab-Compound (Ia) [6]
NeoDegrader P1
Protein cereblon (CRBN)
Isatuximab-Compound (Ia) linker
 ADC Info 
ADC Name Payload Target Linker ADC Info
STI-6129
Duostatin 5.2
Microtubule (MT)
Non-polyethylene glycol linker
 ADC Info 
CD38-077 [11]
Duostatin 5.2
Microtubule (MT)
Non-polyethylene glycol linker
 ADC Info 
Undisclosed
 Antibody Info 
ADC Name Payload Target Linker ADC Info
TAK-169 [12]
Ribosome inactivating SLTA
Ribosome (RB)
Undisclosed
 ADC Info 
TAK-573 [13]
Attenuated form of IFN alpha
Interferon alpha-1/13 (IFNA1; IFNA13)
Undisclosed
 ADC Info 
Anti-CD38 IT OKT10-SAPORIN [14]
Saporin
Microtubule (MT)
Undisclosed
 ADC Info 
References
Ref 1 An Antibody-Drug Conjugate for Multiple Myeloma Prepared by Multi-Arm Linkers
Ref 2 Introduction to basic information on ADC drug CD38 ADC
Ref 3 CD38 antibody-drug conjugates
Ref 4 EDC technology company product EDC8
Ref 5 Introduction to basic information on ADC drug AA-A225
Ref 6 Neodegrader conjugates; 2021-10-07.
Ref 7 ValCitGlyPro-dexamethasone antibody conjugates selectively suppress the activation of human monocytes
Ref 8 Directed conjugation technology
Ref 9 Antibody-drug complexes containing hemiasterlin derivatives
Ref 10 Pharmaceuticals containing antibody-drug complexes containing hemiasterin derivatives
Ref 11 Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies. Blood. 2019 ;134():-. doi: 10.1182/blood-2019-132062.
Ref 12 TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma. Cancer Res (2019) 79 (13_Supplement): 2384.
Ref 13 TAK-573, an Anti-CD38/Attenuated Ifn Fusion Protein, Has Clinical Activity and Modulates the Ifn Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma. Blood (2020) 136 (Supplement 1): 37-38. doi: 10.1182/blood-2020-141219.
Ref 14 Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin. Br J Cancer. 2001 Feb;84(4):571-8. doi: 10.1054/bjoc.2000.1633.